Navigation Links
In the lab and clinic, VCU Massey develops a new therapy for blood cancers
Date:6/2/2011

Richmond, Va. (June 2, 2011) Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

Reported in the journal Clinical Cancer Research, the study determined the maximum tolerated dose with acceptable side effects for this novel drug combination. The trial represented the first time a proteasome inhibitor such as Bortezomib was combined with a cell cycle inhibitor such as Alvocidib to treat patients with cancer.

Proteasome inhibitors work by blocking the action of proteasomes, which are large protein complexes that help destroy proteins that are no longer needed by the cell. Cell cycle inhibitors disrupt the sequence of events that allow cells to undergo cell division and duplication. They also have the ability to block gene transcription.

The trial included 16 patients who had either indolent (non-aggressive) non-Hodgkin's lymphoma, mantle cell lymphoma or multiple myeloma. After they received the treatments over a 21-day cycle, there were two complete responses, meaning that all detectable traces of the cancer were gone, and five partial responses.

"Therapeutic responses tend to be rare in Phase I trials, but 44 percent of our patient sample responded to the therapy. Interestingly, some patients who previously had no response to Bortezomib, or progressed after Bortezomib therapy, responded to the combination," says Beata Holkova, M.D., a hematologist-oncologist at VCU Massey and co-investigator on this clinical trial. "Because of the small patient sample size, we can't draw definitive conclusions about the effectiveness of the therapy, but we were quite encouraged by the results."

The patients received Bortezomib intravenously on days 1, 4, 8 and 11 an
'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Kreativ Dental Clinic, Offering Dental Implant and Dental Services Abroad, Launches 3D Virtual Tours Online
2. VCU Massey research finds new link between inflammation and cancer
3. Key leukemia defense mechanism discovered by VCU Massey Cancer Center
4. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
5. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
6. VCU Massey first to combine targeted agents to kill multiple myeloma cells
7. VCU Massey Cancer Center finds new biomarker that predicts breast cancer relapse
8. Personal Best Develops Workplace Weight Loss Program
9. M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms
10. UD team develops new method for producing proteins critical to medical research
11. UMass Memorial health care develops fully integrated EMR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Pro X . Each preset contains 15 seconds of unique footage that users can ... that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, ...
(Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma injections ... have shown through research to improve treatment outcomes. This localized treatment seems ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... The popular ... James Earl Jones, recently announced that it will be devoting an entire short segment ... affecting millions of people around the globe on a daily basis, but recent advancements ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced today ... and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. ... (VHS) in the United States District Court for the Southern District of Texas ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... DALLAS, Nov. 20 Crdentia Corp. (OTC Bulletin,Board: ... the,promotion of Ms. Penny Kirsch to Vice President ... Human Resources Manager,for Crdentia and will continue to ... Kirsch will be responsible for all human resources ...
... SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a biomaterials company ... delivery products, today,announced that President and CEO Robert P. ... Annual Healthcare Conference at the Palace,Hotel in New York ... EST. Lazard Capital Markets will host a web ...
... System Included in Molecular Imaging Zone, FORT ... (OTC Bulletin Board: IMDS) a pioneer in laser,optical ... will,feature breast cancer cases imaged with optical computed ... November 25 - 28. A CT,Laser Mammography (CTLM(R)) ...
... today the pricing of its public offering of 1,466,400 ... $3.50 per share. Uroplasty,has granted the underwriters a 30-day ... common stock at the offering price to cover,over-allotments. The ... to expand its sales and marketing organization in the ...
... save children,s lives runs through December 8 in all 6,200 ... ... be,participating in the fourth year of the St. Jude Children,s Research,Hospital(R) ... December 8. As part of this national,campaign, CVS/pharmacy has joined with ...
... protein albumin suggests worsening coronary artery disease, study finds ... small amount of a protein called albumin in the ... their risk of cardiovascular death, say U.S. researchers. , ... age 50 and older, with stable coronary artery disease ...
Cached Medicine News:Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 2Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 3Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 2Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 3Health News:Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock 2Health News:CVS/pharmacy Launches St. Jude Thanks and Giving(R) Campaign in Stores Nationwide 2Health News:CVS/pharmacy Launches St. Jude Thanks and Giving(R) Campaign in Stores Nationwide 3Health News:Urine Test Results Can Point to Heart Dangers 2
(Date:8/28/2015)... -- Today, in final recognition of the Centers for Disease ... Contacts is sharing how to keep lens cases clean.  ... do not properly care for their lens cases are ... Most contact lens wearers understand the importance of ... is sometimes overlooked.  When proper steps to clean a ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Quetiapine Market, ... Developed by AstraZeneca plc, quetiapine (under the trade ... the treatment of schizophrenia. Approved by CFDA to ... the Catalogue of Drugs for the Basic National ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Latanoprost ... Developed by Pharmacia & Upjohn in 1995, ... effectively reduces intraocular pressure. As the first pressure- ... trade name of Xalatan) entered China ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... March 25, 2007 /PRNewswire/ -- Once-daily,dosing with ... antagonist, was associated with improvements,in signs and ... hospitalized patients receiving conventional care, without an,adverse ... These,data are from the short- and long-term ...
... BETHESDA, Md., March 26, 2007--Having a build-up of ... heart attacks and,death from heart disease in multiple ... Study of Atherosclerosis (MESA),funded by the National Heart, ... Health. Previous studies have shown that,increased coronary artery ...
Cached Medicine Technology:Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7Calcium Plaque Build-up in the Arteries Leads to Coronary Heart,Disease in Multi-Ethnic Groups 2
Flat Wire Stone Basket...
... Reichert MK1 Keratometer now utilizes ... consistent lighting, removing the need ... we didnt change are all ... made our Keratometer the worldwide ...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
Medicine Products: